New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
08:01 EDTRNAProsensa awarded $200K research grant
Prosensa announced that Judith van Deutekom, Prosensa's vice president of drug discovery, has been awarded a $200K research grant from Parent Project Muscular Dystrophy to fund the development of a multi exon-skipping strategy for exons 10-30 of the dystrophin gene. The project titled "Single AON-induced multiple exon skipping in the mdx mouse model" will focus on obtaining proof-of-concept in the mdx mouse model. The studies are expected to be completed in 2H15.
News For RNA From The Last 14 Days
Check below for free stories on RNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:24 EDTRNAProsensa initiated with an Outperform at Oppenheimer
Subscribe for More Information
July 30, 2014
13:54 EDTRNASarepta surges after FDA says will explore quick approval of DMD drugs
Subscribe for More Information
09:04 EDTRNAFDA says 'willing to explore' accelerated approval for DMD drugs
In response to a White House petition urging the FDA to accelerate approval for safe, effective therapies for children with Duchenne, Janet Woodcock, Director, FDA Center for Drug Evaluation and Research, said in a response, "We are willing to explore the use of all potential pathways for the approval of drugs for Duchenne muscular dystrophy, including accelerated approval, as appropriate." She added, "We share your sense of urgency to make safe and effective drugs available for patients with Duchenne muscular dystrophy as soon as possible. That's why we're actively engaged with a number of drug companies focused on developing new drugs for Duchenne muscular dystrophy, including Sarepta Therapeutics, the company developing eteplirsen, an investigational new drug for Duchenne muscular dystrophy." Shares of Sarepta (SRPT) are trading up 5%, or 97c, to $21.30 in pre-market trading. Yesterday afternoon, Wall Street Journal reported that Sarepta is limiting the role its CEO Chris Garabedian is playing in talks with the FDA. Prosensa (RNA) is also developing a treatment for Duchenne muscular dystroph, or DMD. Reference Link
July 28, 2014
06:35 EDTRNAProsensa upgraded to Buy from Neutral at Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use